Shareholders of Shanghai Bio-heart Biological Technology (HKG:2185) will meet Feb. 13 to vote on the proposed 155.6 million yuan capital injection into unit Zhejiang Bioheart Medical Equipment, a Thursday bourse filing said.
The parties had agreed on earlier in January that Jiaxing Guojian Baixin Equity Investment Partnership Enterprise would make the investment in exchange for a 45.3208% stake in Zhejiang Bioheart.
Price (HKD): $1.55, Change: $+0.010, Percent Change: +0.65%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。